Eosinophilic Esophagitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for eosinophilic esophagitis. 37 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
37
Active US patents
68/100
Avg vulnerability
$2.8B
Annual revenue covered

Originators in Eosinophilic Esophagitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca K.K. 37 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating eosinophilic esophagitis. Each bar = one year. Y-axis scaled to peak year (8 patents).

6
26
2
28
3
29
8
30
6
31
4
36
2
38
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9119863 Pulmicort Respules method of use 93 2026-11-09
8497258 Pulmicort Respules method of use 93 2026-11-09
8975243 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
9415009 Pulmicort Respules method of use 76 2030-05-28
10716753 Pulmicort Respules method of use 76 2030-05-28
11564934 Pulmicort Respules method of use 75 2039-01-10
11896719 Pulmicort Respules method of use 75 2043-01-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10307375 Pulmicort Respules formulation 48 2031-09-07
9132093 Pulmicort Respules formulation 48 2031-09-07
10660858 Pulmicort Respules formulation 48 2031-09-07
11331442 Pulmicort Respules formulation 50 2038-10-05
11833292 Pulmicort Respules formulation 50 2038-10-05
8895064 Pulmicort Respules formulation 53 2031-09-07
12171883 Pulmicort Respules formulation 55 2043-01-23
11260064 Pulmicort Respules formulation 55 2039-01-10
9050368 Pulmicort Respules formulation 61 2029-08-01
10172802 Pulmicort Respules method of use 62 2036-09-09

Related